ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06855 ASCENTAGE-B

Closed 12-17 16:08:10

56.650

-1.050

-1.82%

High57.850	Low55.850	Vol1.75M
Open57.850	D1 Closing57.700	Amplitude3.47%
Mkt Cap21.13B	Tradable Cap21.13B	Total Shares373.00M
T/O99.30M	T/O Rate0.47%	Tradable Shares373.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06855","market":"HK","secType":"STK","nameCN":"ASCENTAGE-B","latestPrice":56.65,"timestamp":1765958890008,"preClose":57.7,"halted":0,"volume":1753026,"delay":0,"floatShares":373000000,"shares":373000000,"eps":-1.4829336352263887,"marketStatus":"Closed","change":-1.05,"latestTime":"12-17 16:08:10","open":57.85,"high":57.85,"low":55.85,"amount":99299043,"amplitude":0.034662,"askPrice":56.7,"askSize":100,"bidPrice":56.65,"bidSize":7400,"shortable":3,"etf":0,"ttmEps":-3.916831994523106,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1766021400000},"marketStatusCode":5,"adr":0,"listingDate":1572192000000,"exchange":"SEHK","adjPreClose":57.7,"openAndCloseTimeList":[[1765935000000,1765944000000],[1765947600000,1765958400000]],"volumeRatio":0.814979,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06855/wiki","defaultTab":"wiki","newsList":[{"id":"1177837504","title":"CICC Maintains \"Outperform\" Rating on ASCENTAGE-B (06855) as POLARIS-1 Gains Approval in US and EU","url":"https://stock-news.laohu8.com/highlight/detail?id=1177837504","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1177837504?lang=en_us&edition=fundamental","pubTime":"2025-12-17 11:57","pubTimestamp":1765943833,"startTime":"0","endTime":"0","summary":"CICC has reiterated its \"Outperform\" rating on ASCENTAGE-B (06855) with a target price of HK$89, citing positive progress in the company's R&D pipeline. The global Phase III study (POLARIS-1) for...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","AAPG","BK4139","BK1161"],"gpt_icon":0},{"id":"2591138655","title":"Is Ascentage Pharma Group International Pricing In Too Much Biotech Optimism After Big 3 Year Rally?","url":"https://stock-news.laohu8.com/highlight/detail?id=2591138655","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591138655?lang=en_us&edition=fundamental","pubTime":"2025-12-14 00:26","pubTimestamp":1765643210,"startTime":"0","endTime":"0","summary":"If you are wondering whether Ascentage Pharma Group International is still a smart way to get exposure to biotech upside, you are not alone. That is exactly what we are going to unpack here.\nDespite a choppy recent stretch, with the share price down 6.8% over the last week and 8.1% over the past month, the stock is still sitting on gains of 35.4% year to date and 53.1% over the last year, building on a 131.9% return over three years.\nRecent moves have been shaped less by day to day trading...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-pricing-in-too-much","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/is-ascentage-pharma-group-international-pricing-in-too-much","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","DCF","06855"],"gpt_icon":0},{"id":"2590341368","title":"Ascentage Pharma Reports Promising Second-Line CML Results for Olverembatinib at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590341368","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590341368?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:31","pubTimestamp":1765287079,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has presented updated clinical data on Olverembatinib, its novel therapy for second-line treatment of chronic myeloid leukemia in chronic-phase , at the 67th American Society of Hematology  Annual Meeting. The results showed a 76.7% complete cytogenetic response rate in patients who had failed first-line therapy with second-generation tyrosine kinase inhibitors . Molecular responses deepened with extended treatment duration, with a major molecular response rate reaching 60% at 21 cycles. The company reported that the efficacy data support the potential for advancing Olverembatinib to earlier lines of treatment for a broader patient population. The findings presented were updates from results previously released at ASH 2024 and included longer follow-up data on efficacy and safety.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251209:nNDL6Xy697:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2589353553","title":"Ascentage Pharma Reports Strong Phase II Results for Lisaftoclax in BTK-Refractory CLL/SLL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589353553","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589353553?lang=en_us&edition=fundamental","pubTime":"2025-12-08 21:02","pubTimestamp":1765198928,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has announced the presentation of pivotal data from a China registrational Phase II study of Lisaftoclax  monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma  who were refractory to Bruton's tyrosine kinase inhibitors . The results, which were presented in an oral report at the 2025 American Society of Hematology  Annual Meeting, showed that Lisaftoclax achieved a 62.5% objective response rate in heavily pretreated, BTKi-refractory patients, nearly half of whom had complex karyotype. The study also reported a median progression-free survival of 23.89 months, with no cases of tumor lysis syndrome observed. The data supported the new drug application  approval of Lisaftoclax by China's National Medical Products Administration in July 2025.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL7jyM40:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"2589487019","title":"Revisiting Ascentage Pharma Group International (SEHK:6855)’s Valuation After Its Strong One-Year Share Price Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=2589487019","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589487019?lang=en_us&edition=fundamental","pubTime":"2025-12-07 16:19","pubTimestamp":1765095588,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) has quietly outperformed over the past year, and with shares up roughly 56% in that time, investors are starting to revisit the story behind this clinical stage biotech.\nSee our latest analysis for Ascentage Pharma Group International.\nThe stock has been choppy in recent months, with a 1 day share price return of 4.44 percent and a 90 day share price return of minus 19.91 percent. However, a 1 year total shareholder return of 55.76 percent...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/revisiting-ascentage-pharma-group-international-sehk6855s-va","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/revisiting-ascentage-pharma-group-international-sehk6855s-va","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["06855","BK1161","BK1574"],"gpt_icon":0},{"id":"2589502058","title":"BUZZ-Ascentage rises on progress of olverembatinib for blood cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2589502058","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589502058?lang=en_us&edition=fundamental","pubTime":"2025-12-05 11:51","pubTimestamp":1764906718,"startTime":"0","endTime":"0","summary":"BUZZ-Ascentage rises on progress of olverembatinib for blood cancer treatment** Shares of Ascentage Pharma Group International 6855.HK rise 6.8% to HK$65, their highest level since November 27** Stock on track for the biggest one-day pct gain since August 5 ** Ascentage receives clearance from US FDA and European Medicines Agency for a phrase III  study of its blood cancer drug olverembatinib** The POLARIS-1 trial is a global, multicenter, randomized controlled, open-label study designed to evaluate the efficacy and safety of olverembatinib in combination with chemotherapy in newly diagnosed patients with certain types of leukemia ** Stock up 37% YTD; Hang Seng Biotech Index .HSBIO up 78.8%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251205:nL1N3XB02Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"1170778758","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 6% as POLARIS-1 Study for Olverembatinib (Nerlynx®) Gains FDA and EMA Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1170778758","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170778758?lang=en_us&edition=fundamental","pubTime":"2025-12-05 09:38","pubTimestamp":1764898699,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 6%, reaching HK$64.2 by the time of writing, with a trading volume of HK$19.93 million. The uptick follows the company's announcement on December 5 that its...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","EMA","BK1574","AAPG","06855","BK4139","BK4081"],"gpt_icon":0},{"id":"1151522256","title":"ASCENTAGE PHARMA-B (06855) Receives FDA and EMA Approval for Global Phase III Trial of Olverembatinib (Nerlynx®) in First-Line Treatment of Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1151522256","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151522256?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:08","pubTimestamp":1764893308,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA-B (06855) announced that its self-developed Class 1 innovative drug, olverembatinib (brand name: Nerlynx®), has received approval from the U.S. Food and Drug Administration (FDA) and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","AAPG","BK4585","BK4107","EMA","BK4588","BK4139","III","06855","BK1574","BK4533","LU0985320562.USD","BK1161","ALL","LU2355687059.USD","LU1699723380.USD","BK4134","BK4081"],"gpt_icon":0},{"id":"1141783167","title":"Ascentage Pharma (6855) Announces Global Phase III Study Clearance for Olverembatinib in First-Line Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=1141783167","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141783167?lang=en_us&edition=fundamental","pubTime":"2025-12-05 08:04","pubTimestamp":1764893094,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (Ascentage Pharma, stock code: 6855) reported that it has received regulatory clearance from both the US Food and Drug Administration (FDA) and the European...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"gpt_icon":0},{"id":"2589685569","title":"Ascentage Pharma Group International - Global Registrational Phase Iii Study of Olverembatinib Cleared by FDA and Ema","url":"https://stock-news.laohu8.com/highlight/detail?id=2589685569","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589685569?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:57","pubTimestamp":1764892668,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nFWN3XA0OS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","06855","BK1574"],"gpt_icon":0},{"id":"2589695855","title":"Ascentage Pharma Wins FDA and EMA Clearance for Global Phase III Study of Olverembatinib in Ph+ ALL","url":"https://stock-news.laohu8.com/highlight/detail?id=2589695855","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589695855?lang=en_us&edition=fundamental","pubTime":"2025-12-05 07:57","pubTimestamp":1764892642,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International has received clearance from both the US Food and Drug Administration  and the European Medicines Agency  to conduct a global registrational Phase III study  of olverembatinib in combination with chemotherapy for the first-line treatment of newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia . This approval enables the company to enroll patients across multiple countries, accelerating the potential registration of olverembatinib in the US and European markets.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stoc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251204:nNDL9mz0pQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06855"],"gpt_icon":0},{"id":"1163465524","title":"Ascentage Pharma (06855) Discloses November Share Capital and Equity Movements","url":"https://stock-news.laohu8.com/highlight/detail?id=1163465524","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163465524?lang=en_us&edition=fundamental","pubTime":"2025-12-04 21:44","pubTimestamp":1764855865,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (06855) released its monthly return on movements in securities for November 2025. The authorized share capital remained at 500,000,000 ordinary shares, each with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"gpt_icon":0},{"id":"1134728285","title":"10th Zhitong Capital Market Annual Conference Honors Excellence with 25 Awards Unveiled","url":"https://stock-news.laohu8.com/highlight/detail?id=1134728285","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134728285?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:38","pubTimestamp":1764761917,"startTime":"0","endTime":"0","summary":"On December 3, 2025, the \"10th Zhitong Capital Market Annual Conference & Listed Companies Awards Ceremony,\" jointly hosted by leading Hong Kong and U.S. stock information platform Zhitong Finance...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02142","IE00B031J352.USD","06657","01177","03680","BK1109","BK1160","LU0175139822.USD","01070","02276","LU0605514214.HKD","06160","LU0791591158.USD","IE0008368742.USD","LU0516422440.USD","SG9999001051.SGD","01939","LU0143863198.USD","01378","BK1526","BK1564","LU0594300179.USD","LU0640798160.USD","LU1242518931.SGD","LU0384037296.USD","LU0516422366.SGD","03145","LU0269904917.USD","LU0828237510.HKD","02598","LU2357125470.USD","01211","06913","BK1553","LU2153591404.USD","LU0511384066.AUD","BK1574","BK1604","LU0231483743.USD","LU0261947096.USD","02167","BK1577","LU1282649810.SGD","BK1183","00960","LU0865486749.SGD","01440","LU0828238088.HKD","BK1559","BK1575","09911","LU0370786039.SGD","01681","BK1521","09639","LU1868838027.USD","01783","00017","02298","02511","LU0315179316.USD","06996","LU0326950275.SGD","LU1366334578.USD","LU1522347837.USD","BK1509","00777","02177","BK1523","LU0541501648.USD","BK1134","09959","LU0762540952.USD","SG9999006514.SGD","02411","LU0572939691.SGD","BK1557","LU0228659784.USD","BK1169","02155","09878","LU0449515922.USD","00020","BK1207","00384","BK1253","LU0819121731.USD","LU1023057109.AUD","03939","09926","BK1161","LU0315178854.USD","IE0031814852.USD","BK1591","LU0251143458.SGD","03836","06090","06058","LU0541502299.USD","01969","LU0499858438.USD","SG9999002463.SGD","LU0244354667.USD","02158","LU0611395673.USD","LU0791590937.USD","BK1235","LU1224709979.USD","LU2348774022.SGD","LU0348766576.USD","BK1222","LU0345775950.USD","01405","LU2328871848.SGD","02150","BK1124","LU0052756011.USD","LU2476274720.SGD","LU0128525689.USD","01585","LU0488056044.USD","BK1240","IE0003795394.USD","06963","IE00BQXX3F31.USD","IE00BGHQDM52.EUR","LU0880133367.SGD","00305","IE00B8L5B284.USD","02157","BK1520","BK1143","LU0011963245.USD","02552","LU0588546209.SGD","LU1861219969.SGD","BK1583","BK1191","LU0164872284.USD","09880","LU0264606111.USD","LU0082770016.SGD","LU0072913022.USD","BK1233","LU0348783233.USD","02020","BK1515","00992","LU1152091754.HKD","LU1115378108.SGD","02469","LU0819123356.HKD","LU1226288170.HKD","BK1194","LU1235295612.USD","06821","BK1147","BK1229","BK1125","SG9999015978.USD","LU0823426480.USD","BK1560","LU3063872942.SGD","01762","LU0634319403.HKD","LU2238339852.HKD","LU0082770016.USD","BK1595","LU0214875030.USD","02273","SG9999001093.SGD","BK1548","06633","BK1148","LU0287142896.SGD","SG9999014674.SGD","IE00BGV7N243.SGD","06168","LU2177674079.SGD","LU1961090484.USD","LU0417516738.SGD","02392","LU2045819591.USD","LU0823414551.USD","LU0823437842.USD","IE00B29SXG58.USD","LU0310800965.SGD","SG9999000475.SGD","LU2039709279.SGD","BK1527","SG9999002950.SGD","01164","06086","BK1237","LU1481107354.HKD","01384","BK1552","LU1831875114.USD","LU2506951792.HKD","01093","BK1605","81211","BK1600","06060","BK1586","LU0164865239.USD","01773","BK1227","LU1675838814.USD","BK1598","SGXZ90724238.SGD","02498","IE00BZ08YS42.EUR","LU2449936058.SGD","06919","BK1214","LU0149721374.USD","02886","LU1226288253.USD","SG9999015952.SGD","02506","LU0143863784.USD","LU2097828631.EUR","LU0043850808.USD","LU0561508036.HKD","09923","LU0348735423.USD","09992","03998","BK1096","BK1212","00798","BK1607","LU1497733631.SGD","LU0314109678.HKD","LU0455707207.USD","LU0211977185.USD","LU1939255532.USD","BK1590","BK1230","BK1592","BK1593","LU0048597586.USD","01809","02616","01448","01640","LU0593848301.USD","LU1634259557.SGD","BK1167","LU0067412154.USD","BK1198","SG9999006597.SGD","02197","BK1228","SG9999015986.USD","LU0543330566.HKD","02228","01600","BK1504","BK1522","LU0463099449.HKD","LNNGY","LU0572944931.SGD","IE00B543WZ88.USD","LU0823414478.USD","02567","00855","LU0254981946.USD","09690","BK1530","BK1200","SG9999011746.SGD","LU0502904849.HKD","00136","BK1139","BK1154","LU1634259391.SGD","BK1168","BK1597","SG9999001903.USD","BK1117","BK1151","LU0456827905.SGD","BK1549","LU0868486357.SGD","BK1110","BK1179","09919","LU0072462343.USD","BK1609","BYDDY","02551","LU0702159699.USD","00699","02590","LU0469268626.HKD","LU2506952253.HKD","01318","HK0000320264.USD","01739","HYDD.SI","02460","LU2476274308.USD","LU2023250504.SGD","SG9999004311.SGD","LU0449509016.USD","BK1618","LU0261950470.USD","LU2663582299.SGD","01877","02145","BK1131","LU1956131251.USD","09890","00999","01471","BK1150","09961","BK1579","LU2399975544.HKD","03800","02565","LU0620787316.HKD","BK1164","BK1257","00382","03658","09678","BK1163","LU2778985437.USD","BK1225","LU0737861772.HKD","02451","BK1516","02190","LU0572940350.SGD","HK0000252152.HKD","00302","LU0456846285.SGD","BK1126","LU1328615791.USD","LU1880383440.USD","IE00BPRC5H50.USD","02650","BK1144","LU0229945570.USD","00003","LU0329678170.USD","LU2460026573.USD","LU0274383008.USD","LU2097828557.USD","02858","06677","LU1188198961.HKD","06608","IE00BYV24P56.USD","LU0417516571.SGD","BK1142","BK1550","LU1282649067.USD","LU1770034418.SGD","00875","IE00B0169L03.USD","LU0501845795.SGD","LU0051755006.USD","09985","00656","82020","00826","00267","LU1226287875.USD","02419","LU1993786604.SGD","IE00BVYPNQ40.USD","03738","BK1186","LU0823038988.USD","LU0594300419.USD","01530","LU2097828805.USD","BK1175","BK1116","LU0588545904.SGD","LU1102505929.USD","BK1589","LU0048580855.USD","LU0289961442.SGD","02018","IE00BQXX3C00.GBP","IE00B8HQ1Z84.USD","LU1917777945.USD","02096","09699","BK1095","BK1585","LU0084288322.USD","LU1770036033.HKD","06988","02431","01651","IE00BQXX3D17.EUR","01458","00512","IE0003851619.USD","BK1555","BK1531","LU0588545490.SGD","LU0871576103.HKD","LU0107464264.USD","LU1242518857.USD","LU1267930227.SGD","LU2008162690.USD","BK1619","BK1136","BK1221","02105","LU0359201885.HKD","HK0000306685.HKD","LU0345776255.USD","LNVGY","03709","06138","01818","LU0540923850.HKD","LU0823397103.USD","02696","LU0261950983.USD","BK1617","LU0329678337.USD","03650","BK1127","LU1039395188.USD","82331","80020","LU0348784397.USD","LU0140636845.USD","LU1008478684.HKD","BK1544","IE0032431581.USD","LU0054450605.USD","LU1880383366.USD","BK1239","00363","BK1195","LU0164880469.USD","03681","09660","LU0505663152.USD","LU0039217434.USD","LU0431992006.USD","LU1211504680.USD","BK1542","02627","86618","IE00B0JY6N72.USD","02488","LU1046422090.SGD","BK1519","SG9999001069.SGD","LU1951186391.HKD","02268","BK1224","BK1258","LU0289960550.SGD","LU0856984785.SGD","LU0531971595.HKD","LU1366334651.USD","SG9999001226.SGD","BK1608","01880","09877","BK1178","LU1303224171.USD","06618","BK1615","BK1524","02256","LU0979878070.USD","BK1582","00460","06186","BK1104","06609","BK1540","LU1497733557.USD","BK1613","BK1502","01907","BK1128","LU1960683339.HKD","BK1588","09990","LU1102505762.USD","BK1189","LU2097828714.EUR","BK1155","LU0516422952.EUR","LU0359201612.USD","02595","LU1508157978.USD","LU0588545730.USD","BK1220","HK0000500386.USD","IE0008369823.USD","02587","IE00BZ08YR35.GBP","00300","IE00BZ08YT58.USD","BK1571","LU1861214812.USD","BK1141","BK1170","02525","LU1497734951.SGD","LU0289739343.SGD","LU1720050803.USD","BK1209","02013","BK1216","02670","LU2097828474.EUR","09927","00666","IE0034224299.USD","LU0823039010.USD","IE0009570106.USD","BK1596","LU0823426308.USD","LU0708995583.HKD","LU0509642566.USD","BK1184","02556","02889","IE00B031HY20.USD","LU1813983027.USD","BK1606","LU0054237671.USD","02331","002594","02250","BK1556","02629","LU0417516902.SGD","BK1247","06613","BK1566","BK1541","BK1610","SGXZ86797644.SGD","SG9999002562.SGD","02400","BK1500","02279","02436","80992","LU0737861699.HKD","01119","06855","LU1166156734.SGD","LU1868837722.USD","01519","BK1616","LU1328277881.USD","03396","LU0165289439.USD","LU0348825331.USD","06862","HK0000306701.USD","06100","LU1974910355.USD","LU2298064838.USD","LU0831093199.SGD","LU1868837565.USD","01911","LU2424517915.HKD","BK1193","LU2242644610.SGD","LU0173614495.USD","01833","09636","ANPDY","LU0307460666.USD","02100","09955","LU0516423091.SGD","LU0823397285.USD","LU0359202008.SGD","BK1137","LU0348805143.USD","SG9999000418.SGD","BK1215","09956","BK1100","01735","BK1219","00451","BK1197","BK1554","LU0052750758.USD","03677","IE00BMCWC346.EUR","LU0348767384.USD","SG9999002828.SGD","02533","HK0000320223.HKD","SG9999015945.SGD","LU0048575426.USD","LU1226287792.SGD","LU1251922891.USD","02171","LU1719994722.HKD","BK1528","LU2348773727.SGD","LU0049112450.USD","LU0348827113.USD","LU2294711713.HKD","LU2360107325.USD","02315","HK0000252160.HKD","02380","BK1171","IE00B5MMRT66.SGD","02382","BK1111","LU1152091168.USD","LU1808992512.USD","01276","00867","01520","BK1587","02453","BK1132","BK1114","02121","BK1140","LU0259732245.USD","00861","00135","SG9999003461.SGD","LU1794554557.SGD","01952","BK1119","SG9999000459.SGD","LU2488822045.USD","BK1594","LU0327786744.USD","02057","LU2106854487.HKD","LU2153592121.USD","06683","LU2543165471.USD","SGXZ62798434.SGD","LU1981816686.USD","HK0000165453.HKD","LU0251144936.SGD","BK1518","09860","01333","BK1158","LU2249611893.SGD","IE00BD6J9T35.USD","LU0650527681.SGD","BK1539","LU0320764599.SGD","LU0499858602.USD","SG9999004220.SGD","LU1969619763.USD","LU1807302812.USD","06069","LU1226287529.USD","09996","01117","BK1512","LU0516423174.USD","LU0531970944.HKD","BK1190","BK1578","LU2125910500.SGD","IE00BVYPNP33.GBP","LU1048588211.SGD","02509","BK1188","03896","LU0164939612.USD","00884","02420"],"gpt_icon":1},{"id":"1195526525","title":"ASCENTAGE PHARMA GROUP-B (06855) Grants 1.3045 Million Restricted Share Units and 736,600 Share Options","url":"https://stock-news.laohu8.com/highlight/detail?id=1195526525","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195526525?lang=en_us&edition=fundamental","pubTime":"2025-11-27 21:24","pubTimestamp":1764249856,"startTime":"0","endTime":"0","summary":"ASCENTAGE PHARMA GROUP-B (06855) announced that, as of the date of this announcement, it has granted 1.3045 million restricted share units under the 2022 Restricted Share Unit Plan to 146 selected...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","BK4139","AAPG","06855"],"gpt_icon":0},{"id":"1142202410","title":"Ascentage Pharma (6855) Announces Additional RSU and Share Option Grants","url":"https://stock-news.laohu8.com/highlight/detail?id=1142202410","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142202410?lang=en_us&edition=fundamental","pubTime":"2025-11-27 21:22","pubTimestamp":1764249750,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (Stock Code: 6855) disclosed a further grant of restricted share units (RSUs) under its 2022 RSU Scheme and a grant of share options under its Post-IPO Share...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06855"],"gpt_icon":0},{"id":"2586210175","title":"Assessing Ascentage Pharma (SEHK:6855) Valuation Following Major Data Publication on Olverembatinib in Rare GIST Subtype","url":"https://stock-news.laohu8.com/highlight/detail?id=2586210175","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586210175?lang=en_us&edition=fundamental","pubTime":"2025-11-27 14:33","pubTimestamp":1764225234,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) garnered investor interest after publishing new data from a Phase Ib study for its drug olverembatinib in patients with SDH-deficient gastrointestinal stromal tumors.\nSee our latest analysis for Ascentage Pharma Group International.\nFollowing the announcement of encouraging new results for olverembatinib, Ascentage Pharma Group International has continued to capture investor attention, even as its share price has pulled back 6.4% over the past...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/assessing-ascentage-pharma-sehk6855-valuation-following-majo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","06855"],"gpt_icon":0},{"id":"1126789920","title":"Hong Kong Stock: ASCENTAGE-B Rises Over 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=1126789920","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126789920?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:21","pubTimestamp":1764127283,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855.HK) surged more than 3% in Hong Kong trading. At the time of writing, the stock was up 3.04% to HK$64.35, with a turnover of HK$46.05 million.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","AAPG","06855","BK4139"],"gpt_icon":0},{"id":"1182587677","title":"HK Stock Movement | ASCENTAGE-B (06855) Rises Over 3% as Study Reveals Novel Mechanism of Olverembatinib's Anti-Tumor Effects via Lipid Metabolism Regulation","url":"https://stock-news.laohu8.com/highlight/detail?id=1182587677","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1182587677?lang=en_us&edition=fundamental","pubTime":"2025-11-26 11:00","pubTimestamp":1764126017,"startTime":"0","endTime":"0","summary":"ASCENTAGE-B (06855) surged more than 3%, reaching HK$64.35 by the time of writing, with a trading volume of HK$46.05 million. The company announced on November 25 that research findings from the...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","06855","BK1161","BK1574","AAPG"],"gpt_icon":0},{"id":"2584948036","title":"Asian Growth Companies With High Insider Ownership In November 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2584948036","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584948036?lang=en_us&edition=fundamental","pubTime":"2025-11-17 06:08","pubTimestamp":1763330896,"startTime":"0","endTime":"0","summary":"As Asian markets navigate a landscape marked by economic challenges and investor caution, the focus on insider ownership becomes increasingly relevant. In this context, companies with significant insider stakes can offer insights into potential growth opportunities, as they often reflect confidence from those closest to the business.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/asian-growth-companies-with-high-insider-ownership-in-novemb-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/asian-growth-companies-with-high-insider-ownership-in-novemb-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2583568100","title":"Ascentage Pharma (SEHK:6855): Evaluating Valuation After ASH Meeting Spotlights Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2583568100","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583568100?lang=en_us&edition=fundamental","pubTime":"2025-11-13 15:38","pubTimestamp":1763019485,"startTime":"0","endTime":"0","summary":"Ascentage Pharma Group International (SEHK:6855) saw attention rise after announcing that new clinical and preclinical results on olverembatinib, lisaftoclax, and APG-5918 will be featured at the 67th ASH Annual Meeting. This recognition for its drug candidates highlights the company’s development programs and keeps them in focus for investors.\nSee our latest analysis for Ascentage Pharma Group International.\nThis spotlight at ASH comes after a year of strong momentum for Ascentage Pharma...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/ascentage-pharma-sehk6855-evaluating-valuation-after-ash-mee","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6855/ascentage-pharma-group-international-shares/news/ascentage-pharma-sehk6855-evaluating-valuation-after-ash-mee","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","BK1161","BK4109","06855","ASH","PRGS","LU2065732104.USD","LU2463526074.USD","BK4097"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentagepharma.com","stockEarnings":[{"period":"1week","weight":-0.027},{"period":"1month","weight":-0.1458},{"period":"3month","weight":-0.2423},{"period":"6month","weight":-0.1827},{"period":"1year","weight":0.4738},{"period":"ytd","weight":0.2695}],"compareEarnings":[{"period":"1week","weight":-0.0078},{"period":"1month","weight":-0.0503},{"period":"3month","weight":-0.0622},{"period":"6month","weight":0.086},{"period":"1year","weight":0.2748},{"period":"ytd","weight":0.258}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Ascentage Pharma Group International is a holding company primarily engaged in discovering, developing and commercializing therapies primarily in hematological malignancies. The Company’s main business is engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus and certain age-related diseases. The Company’s main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918 and other products. The Company’s products are mainly used to address the major hematological malignancies, including chronic myeloid leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and multiple myeloma. The Company mainly conducts its business in the domestic market.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.093585},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.035469},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.10554},{"month":4,"riseRate":0.833333,"avgChangeRate":0.119495},{"month":5,"riseRate":0.5,"avgChangeRate":0.054537},{"month":6,"riseRate":0.833333,"avgChangeRate":0.306068},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.077026},{"month":8,"riseRate":0.833333,"avgChangeRate":0.051008},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.083178},{"month":10,"riseRate":0.5,"avgChangeRate":0.039816},{"month":11,"riseRate":0.428571,"avgChangeRate":0.061723},{"month":12,"riseRate":0.571429,"avgChangeRate":0.058487}],"exchange":"SEHK","name":"ASCENTAGE-B","nameEN":"ASCENTAGE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ASCENTAGE-B(06855) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ASCENTAGE-B,06855,ASCENTAGE-B股票,ASCENTAGE-B股票老虎,ASCENTAGE-B股票老虎国际,ASCENTAGE-B行情,ASCENTAGE-B股票行情,ASCENTAGE-B股价,ASCENTAGE-B股市,ASCENTAGE-B股票价格,ASCENTAGE-B股票交易,ASCENTAGE-B股票购买,ASCENTAGE-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ASCENTAGE-B(06855),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ASCENTAGE-B(06855) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}